Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Work In Process (2021 - 2026)

Aytu Biopharma has reported Work In Process over the past 5 years, most recently at $1.8 million for Q4 2025.

  • Quarterly Work In Process fell 41.48% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, down 41.48% year-over-year, with the annual reading at $1.4 million for FY2025, 75.88% down from the prior year.
  • Work In Process was $1.8 million for Q4 2025 at Aytu Biopharma, up from $862000.0 in the prior quarter.
  • Over five years, Work In Process peaked at $5.7 million in Q2 2024 and troughed at $862000.0 in Q3 2025.
  • The 5-year median for Work In Process is $2.8 million (2022), against an average of $2.8 million.
  • Year-over-year, Work In Process soared 93.67% in 2024 and then crashed 75.88% in 2025.
  • A 5-year view of Work In Process shows it stood at $2.2 million in 2021, then increased by 28.99% to $2.8 million in 2022, then decreased by 4.6% to $2.7 million in 2023, then rose by 16.04% to $3.1 million in 2024, then plummeted by 41.48% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Work In Process are $1.8 million (Q4 2025), $862000.0 (Q3 2025), and $1.4 million (Q2 2025).